Crossmark

Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial

Crossref DOI link: https://doi.org/10.1038/s43856-025-01186-x

Published Online: 2025-11-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Topal, Halit

Venken, Tom https://orcid.org/0000-0003-0773-1810
Bassez, Ayse

Chiritescu, Gabriela

Van Cutsem, Eric

van der Merwe, Schalk

Lambrechts, Diether https://orcid.org/0000-0002-3429-302X
Topal, Baki https://orcid.org/0000-0002-2687-7535
Funding

Funding for this research was provided by:

Stichting Tegen Kanker
License Information

Text and Data Mining valid from 2025-11-18

Version of Record valid from 2025-11-18
More Information

Article History

Received: 21 January 2025

Accepted: 2 October 2025

First Online: 18 November 2025

Competing interests

: The authors declare no competing interests. ASTRA-ZENECA NV/SA and Stichting tegen Kanker were not involved in any stage of the study.

Document is current

Any future updates will be listed below